Existing Sunscreen Monograph Ingredients Could Fail Proposed Safety Standards
This article was originally published in The Rose Sheet
Executive Summary
FDA’s proposed safety standards for sunscreen monograph ingredients might not align with safety evidence supporting current monograph ingredients. Without a safeguard, such as a grandfather clause, these ingredients could face challenges if FDA adopts stricter standards, NDAC committee members worry.
You may also be interested in...
Adverse-Event Data Requirement Among Sunscreen TEA Bugs – FDA
The significant time and resources necessary to amend the monograph are one reason for FDA’s slow response to time and extent applications to add ingredients to the OTC sunscreen monograph, agency officials say. Another reason may be flawed data requirements in the application process, with the requirement for adverse-event reports cited as a particular challenge for both sponsors and the agency.
Sunscreen Safety Framework Is FDA’s First Step, With More Tests Needed – NDAC
NDAC members agree with FDA’s proposed standards for evaluating the safety of sunscreen monograph ingredients, but suggest the agency add tests to evaluate the impact of long-term use, actual use and bioavailability in specific populations.
FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda
FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.